Genentech's Herceptin gets approval in U.S.
Genentech Inc. won unusually swift U.S. Food and Drug Administration approval to market its breast cancer drug, Herceptin, the first rifleshot attack on underlying causes of the disease. The drug,
Genentech Inc. won unusually swift U.S. Food and Drug Administration approval to market its breast cancer drug, Herceptin, the first rifleshot attack on underlying causes of the disease. The drug,